Swiss National Bank Boosts Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Swiss National Bank grew its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 4.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 112,600 shares of the company’s stock after buying an additional 4,500 shares during the quarter. Swiss National Bank’s holdings in Viridian Therapeutics were worth $2,159,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. FMR LLC lifted its holdings in Viridian Therapeutics by 16.8% in the 3rd quarter. FMR LLC now owns 11,183,478 shares of the company’s stock valued at $254,424,000 after purchasing an additional 1,610,130 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new stake in shares of Viridian Therapeutics in the third quarter valued at about $9,669,000. Victory Capital Management Inc. purchased a new position in shares of Viridian Therapeutics in the fourth quarter worth about $7,868,000. Lord Abbett & CO. LLC acquired a new position in Viridian Therapeutics during the third quarter worth about $8,917,000. Finally, Raymond James Financial Inc. purchased a new stake in Viridian Therapeutics during the 4th quarter valued at about $6,015,000.

Wall Street Analysts Forecast Growth

VRDN has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Royal Bank of Canada lifted their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 17th. Wells Fargo & Company restated an “equal weight” rating and issued a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Stock Up 3.6 %

Shares of VRDN opened at $14.67 on Friday. The company’s 50-day moving average price is $16.82 and its 200 day moving average price is $19.70. Viridian Therapeutics, Inc. has a 12-month low of $11.40 and a 12-month high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.20 billion, a P/E ratio of -3.40 and a beta of 1.05.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.